26 November 2024 - Otsuka announces the submission of a new drug application to the Japanese Ministry of Health, Labour and Welfare for the manufacture and sale in Japan of bempedoic acid for the treatment of hypercholesterolaemia and familial hypercholesterolaemia.

In 2020, Otsuka acquired exclusive development and commercialisation rights for bempedoic acid in Japan from Esperion and is currently developing it domestically.

Read Otsuka press release